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Abstract
Background: Although the mechanistic details of the vesicle transport process from the cell body to the nerve
terminal are well described, the mechanisms underlying vesicle traffic within nerve terminal boutons is relatively
unknown. The actin cytoskeleton has been implicated but exactly how actin or actin-binding proteins participate in
vesicle movement is not clear.
Results: In the present study we have identified Nonmuscle Myosin II as a candidate molecule important for
synaptic vesicle traffic within Drosophila larval neuromuscular boutons. Nonmuscle Myosin II was found to be
localized at the Drosophila larval neuromuscular junction; genetics and pharmacology combined with the time-
lapse imaging technique FRAP were used to reveal a contribution of Nonmuscle Myosin II to synaptic vesicle
movement. FRAP analysis showed that vesicle dynamics were highly dependent on the expression level of
Nonmuscle Myosin II.
Conclusion: Our results provide evidence that Nonmuscle Myosin II is present presynaptically, is important for
synaptic vesicle mobility and suggests a role for Nonmuscle Myosin II in shuttling vesicles at the Drosophila
neuromuscular junction. This work begins to reveal the process by which synaptic vesicles traverse within the
bouton.
Background
Transport and assembly of synaptic vesicles has been
the subject of several studies. Vesicles and their compo-
nents are transported along axon microtubules to the
nerve terminal, (for review see [1,2]) where they partici-
pate in synaptic physiology, undergoing a cycle of exo-
and endocytosis. However, vesicle traffic within terminal
boutons is not well understood although recent
advances in this area have been made [3,4].
Classically, vesicles were believed to be relatively sta-
tionary until released [5-7]. However, more recent stu-
dies provided evidence for a mobile vesicle pool [8,9]
best described by a caged-diffusion model [10] and dif-
ferential vesicle mobility in the reserve and recycling
pool has been suggested within the frog motor nerve
terminals [11]. Additionally, Nunes et al. [12] observed
dynamic vesicles in the Drosophila melanogaster bouton,
and dynamic vesicles have been reported at ribbon
synapses in lizards [13].
Vesicle movement may result from diffusion or direc-
ted transport. Actin polymerization in the nerve term-
inal may promote vesicle movement through a Listeria
comet mechanism [14] or it may act as a substrate for
myosin motors to shuttle vesicles. In light of a previous
screen from our lab identifying Nonmuscle Myosin II
(NMMII) as a candidate molecule important in neuro-
muscular junction (NMJ) development [15,16], we have
focused on determining a neuromuscular function for
this actin-based myosin motor. NMMII is present in the
nervous system of Xenopus, mouse, rat and chicken
[17-19], and in the CNS of Drosophila [20]. NMMII can
both crosslink F-actin and has been shown to transport
vesicles on F-actin [21-23].
This study was undertaken to determine whether
NMMII contributes to synaptic vesicle mobility. We
used the genetic model system Drosophila melanogaster
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to manipulate NMMII expression, pharmacology to
inhibit NMMII activity, and the optically accessible neu-
romuscular synapse of third instar larvae to investigate
vesicle dynamics. We show that NMMII is concentrated
pre- and postsynaptically and importantly, we report
that unstimulated synaptic vesicle mobility exhibited a
dependence on NMMII expression. These results report
the first evidence for NMMII having a function in
synaptic vesicle dynamics at the Drosophila NMJ.
Results
Nonmuscle Myosin II is localized pre- and
postsynaptically at the NMJ
Although NMMII has been previously found in the Dro-
sophila CNS [20], it has not been previously localized to
the NMJ. Therefore we used immunocytochemistry to
investigate the localization of NMMII at the NMJ (Fig-
ure. 1). First, we demonstrated the presence of NMMII
by staining the NMJ with anti-NMMII and found a
robust signal labelling the nerve terminal, which co-
localized to a high degree with anti-HRP, a general mar-
ker of insect neural membrane. We did notice however
that some of the NMMII staining was found outside the
boutons defined by the anti-HRP signal suggesting that
some of the NMMII signal has a postsynaptic origin. To
further investigate this possibility we double labelled the
NMJ with the post-synaptic marker, Discs large and
anti-NMMII. We found colocalization between Discs
large and NMMII, indicating NMMII is found post-
synaptically. To determine whether NMMII is also
found presynaptically, we expressed UASzipRNAi in the
muscle using the muscle specific driver 24BGal4. This
dramatically reduces NMMII in the muscle, revealing
presynaptic NMMII, which colocalizes with the specific
neural marker anti-HRP. Together these results demon-
strate the presence of NMMII at the Drosophila NMJ.
Expression level of Nonmuscle Myosin II in zipper alleles
In order to study NMMII we manipulated its expression
level using genetic tools. In Drosophila, NMMII is
encoded by the zipper (zip) gene. We used the heterozy-
gous loss-of-function zip1 allele (Het), overexpressed zip
with the zip transgene, zipGS50077 (O/E), and expressed a
zip knockdown construct, zipRNAi (K/D). Before pro-
ceeding with using these reagents in experiments we
confirmed the different zip tools were functioning as
expected by western blot analysis of protein prepared
from larval brain extracts (Figure. 2). NMMII expression
in elav3AGal4 (ct) larvae were used as a control and
normalized to 1.00. RNAi Knockdown of NMMII signif-
icantly reduced the NMMII level to 28% (K/D, 0.28 ±
0.05, n = 5) of the control. The heterozygous loss-of-
function allele zip1/CyO reduced NMMII expression to
57% (Het, 0.57 ± 0.07, n = 4) of the control while over-
expression of NMMII increased protein levels by 95%
compared (O/E, 1.95 ± 0.25, n = 4) to elav3AGal4 (ct)
(Figure 2). Statistical analysis revealed significant varia-
tion among the groups (ANOVA, p < 0.0001), while
post hoc Newman-Keuls comparison between groups
showed that each group was different from the other (at
least p < 0.05) with the exception that zip1/CyO was not
found to be statistically different from the knockdown
sample despite the 50% difference in average protein
levels.
Inhibition of Myosin with ML-9 results in a
dose-dependent decrease in vesicle mobility
NMMII has been previously shown to function in NMJ
development [15,16]. For this reason, we investigated
whether NMMII affected vesicle dynamics at the Droso-
phila NMJ. To assess the effects of NMMII on vesicle
dynamics, synaptic vesicle mobility was measured using
FRAP under conditions of altered Myosin activity. To
visualize synaptic vesicles in vivo, the recombinant
synaptotagmin-GFP construct, elavC155Gal4; UAS-
sytGFP, was used to drive expression of synaptotagmin-
GFP in the nervous system. Synaptotagmin-GFP has
previously been shown to mark synaptic vesicles [12,24].
To begin our examination of myosin activity at the
synapse we used ML-9, an inhibitor of myosin light
chain kinase (MLCK), and tested synaptic vesicle mobi-
lity under different doses of this Myosin inhibitor
(Figure 3A). Application of ML-9 to elavC155Gal4; UAS-
sytGFP/Y larvae resulted in a dose-dependent reduction
in the mobility of synaptic vesicles compared to vesicle
dynamics in a saline + DMSO control (Figure 3B). Vesi-
cle mobility in this saline + DMSO treated control (n =
20 boutons, 4 larvae) did not significantly differ from
the saline only control (n = 22 boutons from 4 larvae, P
> 0.05) used here in the subsequent FRAP experiments.
A significant decrease in vesicle mobility was observed
with 100 μM ML-9, which resulted in the most dramatic
reduction of vesicle mobility (n = 20 boutons from 4
larvae, P < 0.05) while 50 μM ML-9 resulted in slightly,
but significantly less vesicle mobility (n = 20 boutons
from 4 larvae, P < 0.05) compared to the control. A
dose of 10 μM ML-9 (n = 20 boutons from 4 larvae,
P > 0.05) had no effect on vesicle dynamics (Figure 3B,
Table 1 and Additional files 1 and 2 for example movies
of vesicle dynamics with control and 100 μM ML-9).
Together this indicates a dose-dependent response of
vesicle mobility to Myosin inhibition. ML-9 is a general
Myosin inhibitor while (-)-Blebbistatin is known to be
selective towards inhibiting NMMII [25]. However
(-)-Blebbistatin is autofluorescent under blue light and is
quickly deactivated upon exposure to blue light [26,27]
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Figure 1 NMMII is localized pre- and postsynaptically at the NMJ. a-NMMII (red) was found to colocalize with the neural marker a-HRP
(green). a-NMMII staining is observed which did not colocalize with a-HRP (merge) suggesting NMMII is also present postsynaptically (top row).
The postsynaptic marker a-Dlg (green) is observed to colocalize (merge) with a-NMMII (red) suggesting NMMII is present postsynaptically
(second row). To confirm presynaptic expression of NMMII, UASzipRNAi was expressed postsynaptically using 24BGal4 (bottom row). This
eliminated postsynaptic expression of NMMII. Immunocytochemistry revealed that while postsynaptic staining of NMMII had been eliminated,
NMMII was still present presynaptically as seen with the colocalization with a-HRP (merge). No postsynaptic NMMII is visible in the merged
image. The top and bottom rows are shown as confocal stacks, while the middle two rows are shown as single confocal slices.
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thus limiting our ability to use this drug with our FRAP
conditions. We did however obtain NMMII alleles to
determine their affect on vesicle mobility.
Nonmuscle Myosin II contributes to synaptic vesicle
dynamics
In order to clarify whether NMMII was contributing to
the inhibition of vesicle dynamics by ML-9, we geneti-
cally combined elavC155Gal4;UAS-sytGFP with the
NMMII alleles; zip1, UASzipRNAi and zipGS50077. This
allowed us to visualize the affect on vesicle dynamics
when NMMII expression was altered (Figure 4A). When
NMMII levels are knocked down using elavC155Gal4;
UAS-sytGFP/+; UASzipRNAi/+ (K/D, n = 26 boutons
from 5 larvae) the rate of vesicle movement is signifi-
cantly reduced compared to the elavC155Gal4;UAS-
sytGFP/Y (ct, n = 19 boutons from 4 larvae, P < 0.05)
control. Surprisingly, vesicle dynamics were also reduced
(O/E, n = 23 boutons from 5 larvae, P < 0.0001) when
NMMII is overexpressed using elavC155Gal4;UAS-
sytGFP/+; zipGS50077/+. Interestingly, the heterozygous
loss-of-function NMMII allele, zip1/+ resulted in
enhanced mobility of vesicles (Het, n = 21 boutons from
4 larvae, P < 0.05) (Figure. 4B, Table 1 and Additional
files 1, 3, 4 and 5 for example movies of vesicle
dynamics with NMMII manipulation).
Although the bleach depth was not significantly differ-
ent between the heterozygous loss-of-function allele, the
RNAi knockdown sample and control samples, the O/E
samples did show significantly lower bleach depth (See
Additional file 6, Figure S1A showing the average bleach
depth from FRAP experiments). We therefore further
analysed the FRAP recoveries to ensure differences in
bleach depth did not account for our results. To refine
Figure 2 Quantification of NMMII alleles. Western blot of NMMII alleles a, Knockdown (K/D) of NMMII in the nervous system reduced NMMII
expression to 28% (n = 5, P < 0.05) whereas the heterozygous loss-of-function zip1/CyO (Het) reduced NMMII expression to 57% (n = 4, P < 0.05)
compared to the elav3AGal4 control (ct). Overexpression of zipGS50077 (O/E) in the nervous system increased NMMII expression by 95% (n = 4, P <
0.05) compared to the elav3AGal4 control (ct). a-b-Tubulin was used as the loading control. Relative NMMII proteins levels were quantified from
the western blot analysis. Each band was first normalized to the level of b-tubulin (used as a loading control, not shown) and then the mutant
genotypes were normalized to elav3AGal4 protein levels, which were set to 1. The bars indicate the mean level obtained from 4-5 samples, bars
are SEM. Overexpression (O/E), knockdown (K/D), heterozygous loss-of-function (Het).
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our analysis, we calculated the recovery index of the
FRAP curve [12] which accounts for differences in
bleach depth between genotypes. These calculations led
to the same conclusions: the heterozygous loss-of-func-
tion allele of NMMII increased the recovery index,
while both the RNAi knockdown and overexpression
of NMMII reduced the recovery index (See Additional
file 6, Figure S1B showing the recovery index from the
FRAP curves).
Overall these results indicate that NMMII contributes
to vesicle mobility in a manner which is highly depen-
dent on the expression level of NMMII (Table 2).
Discussion
This report has identified the presence of NMMII in the
presynaptic terminal and indicates a function for
NMMII in synaptic vesicle mobility at the NMJ of Dro-
sophila melanogaster. NMMII has been implicated in
synaptic transmission in rats [19], but has not previously
been shown at the NMJ of Drosophila and this is the
first evidence of NMMII having a function in synaptic
vesicle mobility. Using Drosophila, as a genetically mal-
leable tool, and the confocal imaging technique, FRAP,
we were able to quantify the effect of NMMII on vesicle
mobility. FRAP revealed that NMMII plays a complex
Figure 3 FRAP indicating the mobility of vesicles in response to application of the Myosin inhibitor, ML-9. a, Acquired images for the
recovery of fluorescently labelled vesicles using elavC155Gal4;UAS-sytGFP/Y after application of ML-9. Images are shown immediately before
bleaching (8 sec), immediately after photobleaching (10 sec) and at 16, 48 and 120 sec. Bleached areas are indicated by white arrows. A
reduction in recovery is observed with increasing doses of ML-9. b, A significant dose-dependent response was observed for inhibition with ML-
9 between the doses of 100 μM ML-9 and 10 μM ML-9 as compared to 0 μM ML-9. 10 μM ML-9 did not significantly reduced vesicle mobility.
Error is represented as the 95% confident interval of the curve. FRAP recoveries were fit with double exponential curves and nonlinear regression
was used to test for statistical differences. Sample sizes and significance were as follows: 0 μM ML-9 (n = 20), 10 uM ML-9 (n = 22, p > 0.05),
50 μM ML-9 (n = 20, p < 0.05), 100 μM ML-9 (n = 20, p < 0.05).
Table 1 Rate parameters from FRAP curves fit with the double exponential curves
Treatment Rate Parameters1
A K1 B K2
Vesicle Mobility
0 μM ML-9 0.38 ± 0.031 0.0040 ± 0.0010 0.72 ± 0.031 0.11 ± 0.40
10 μM ML-9 0.37 ± 0.0035 0.0035 ± 0.0010 0.40 ± 0.083 0.080 ± 0.023
50 μM ML-9 0.39 ± 0.030 0.0025 ± 0.0010 0.42 ± 0.087 0.080 ± 0.022
100 μM ML-9 0.51 ± 0.020 0.0025 ± 0.0005 0.29 ± 0.16 0.11 ± 0.050
Control (ct) 0.40 ± 0.033 0.0047 ± 0.0012 0.58 ± 0.22 0.10 ± 0.039
Heterozygous Loss-of-Function (Het) 0.37 ± 0.043 0.0069 ± 0.0015 0.66 ± 0.33 0.12 ± 0.049
RNAi Knockdown (K/D) 0.46 ± 0.035 0.0031 ± 0.0008 0.28 ± 0.12 0.082 ± 0.045
Overexpression (O/E) 0.49 ± 0.040 0.0023 ± 0.0010 0.35 ± 0.093 0.071 ± 0.030
1 Equation: Frap(t) = 1-A(e-K1 off t)-B(e-K2 off t) [38] where A, B = constants that represent the apparent bleached fraction, K1, K2 = rates, t = time
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Figure 4 FRAP recovery curves for vesicle mobility when NMMII expression is altered. a, Acquired images for the recovery of the
heterozygous loss-of-function, elavC155Gal4;UAS-sytGFP/+; zip1/+ (Het), the control, elavC155Gal4;UAS-sytGFP/Y (ct), the RNAi knockdown,
elavC155Gal4;UAS-sytGFP/+;UASzipRNAi/+ (K/D) and the overexpression, elavC155Gal4;UAS-sytGFP/+; zipGS50077/+ (O/E) of NMMII immediately before
bleaching (8 sec), immediately after photobleaching (10 sec) and at 12, 16, 48 and 120 sec post-bleaching. Bleached areas are indicated with
white arrows. At 16 sec the bleached region for Het is no longer visible; however, it is still clearly visible in control (ct). At 120 sec, the bleached
region is no longer visible in the control (ct), but is still visible for both K/D and O/E. b, Vesicle mobility is affected by the expression level of
NMMII. FRAP curves reveal that the heterozygous NMMII loss-of-function (Het) significantly enhanced vesicle mobility as compared to the control
(ct) while both knockdown (K/D) and overexpression (O/E) of NMMII significantly reduced vesicle mobility. FRAP recoveries were fit with double
exponential curves. Nonlinear regression was used to test for statistical differences; elavC155Gal4;UAS-sytGFP/Y (n = 26), elavC155Gal4;UAS-sytGFP/+;
zip1/+ (n = 24, p < 0.05), elavC155Gal4;UAS-sytGFP/+;UASzipRNAi/+ (n = 22, p < 0.05), elavC155Gal4;UAS-sytGFP/+; zipGS50077/+ (n = 20, p < 0.05).
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role in vesicle dynamics and begins to clarify our knowl-
edge of how synaptic vesicles may be available for
release upon stimulation.
Vesicle mobility is affected by a complex interaction with
Nonmuscle Myosin II
Immunocytological staining first identified that NMMII
is found both pre- and postsynaptically in the Droso-
phila NMJ. Abolishment of postsynaptic NMMII expres-
sion through RNAi confirmed expression of NMMII
presynaptically. With NMMII present in the presynaptic
terminal, this suggests a possible function for NMMII in
trafficking vesicles within the bouton. To determine
whether NMMII impacts vesicle dynamics, we carried
out in vivo imaging techniques to visualize synaptic vesi-
cle mobility. We found an intriguing complex interac-
tion between the expression level of NMMII and the
dynamics of vesicle mobility. Inhibiting MLCK reduced
vesicle mobility, consistent with Jordan et al. [10]. More
specifically, increasing either NMMII expression by 95%
or reducing NMMII expression to 28% reduced vesicle
mobility, while moderately reducing NMMII to 57%
enhanced vesicle mobility. A limitation of the present
study is an estimate of NMMII activity or levels specifi-
cally at nerve terminal boutons in the various mutant
strains used. The postsynaptic presence of NMMII
makes immunohistochemical techniques for measuring
presynaptic NMMII difficult. We estimated neuronal
NMMII levels using western blots of larval brains. This
demonstrated that NMMII levels were up- and down-
regulated significantly by the genotypes used. The 50%
reduction in protein level from the heterozygous loss-of-
function to the RNAi knockdown strains did not exhibit
a statistical difference. However, we did find substan-
tially different effects on vesicle mobility suggesting that
the apparent difference in expression levels is function-
ally significant. Thus it appears that tight regulation of
NMMII expression is essential in maintaining appropri-
ate vesicle dynamics: a small reduction in NMMII levels
enhances mobility whereas too much or too little
impairs mobility. Together this supports a role for
NMMII in normal synaptic vesicle mobility at the Dro-
sophila NMJ.
While these findings suggest a role for NMMII in
synaptic vesicle mobility, it does not exclude the possibi-
lity that other myosin motors are also involved. In sup-
port of this, the general myosin inhibitor, ML-9,
reduced synaptic vesicle mobility in a dose dependent
manner with no stimulation of vesicle mobility at low
concentrations. In addition, other myosin motors have
been shown to associate with synaptic vesicles and be
involved in synaptic transmission. For example, Myosin
V can bind to a myosin receptor found on a subpopula-
tion of high density vesicles [28] and is found to be
associated with vesicles isolated from chick brain [29],
but was not found to alter hippocampal synaptic trans-
mission in mice [30]. However, Myosin II has been asso-
ciated with normal synaptic transmission. In cultured rat
superior cervical ganglion neurones, myosin IIb was
found to inhibit synaptic transmission [19]. A reduction
in synaptic transmission upon inhibition of Myosin II
was also observed in rat cholinergic synapses [31], while
MLCK was found to be involved in maintaining repeti-
tive synaptic transmission [32]. Myosin II has also been
shown to be involved in vesicle mobility in other sys-
tems. Nonmuscle Myosin II has been shown to trans-
port vesicles on actin filaments in clam oocytes [22] and
Nonmuscle Myosin II has been shown to contribute to
vesicle transport from the Golgi to the Endoplasmic
Reticulum [23]. Thus, while the present work identifies
a function for NMMII in synaptic vesicle mobility, the
precise mechanisms of myosin motors in synaptic trans-
mission and the precise role of NMMII as a vesicle
motor remains to be clarified. Since NMMII interacts
with actin, it will also be important to investigate the
affects of NMMII on actin stability and dynamics in the
NMJ and to determine whether the affects of NMMII
on vesicle mobility translate into affects on synaptic
transmission.
Conclusions
Our results show that NMMII is found presynaptically
at the Drosophila NMJ and plays a functional role at the
NMJ. We report, for the first time, a function for
NMMII in normal synaptic vesicle mobility in the unsti-
mulated neuron, which is dependent on the expression
level of NMMII. Further experimentation to address the
function of NMMII at the NMJ, through electrophysio-
logical assays, manipulating NMMII activity by its’
kinases and phosphatases and measuring actin activity,
is required to more clearly define the precise role of
NMMII at the Drosophila NMJ.
Table 2 Summary of results from manipulating NMMII
expression




↑ = increased relative to control, ↓ = decreased relative to control,
↓↓ = further decreased relative to control
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Methods
Drosophila Stocks
Drosophila melanogaster were maintained at 22°C on
Bloomington fly media. The heterozygous loss-of-func-
tion NMMII allele, zipper1/CyO (zip1/CyO)
(FBal0018862) was acquired from the Bloomington
stock center and rebalanced over Cyo-GFP. UASzipperR-
NAi (UASzipRNAi) was obtained from the Vienna Dro-
sophila RNAi center (FBst0470845) and is a NMMII
RNAi construct. The gain-of-function NMMII construct,
zipperGS50077(zipGS50077), was obtained from the Droso-
phila gene search project [33] and is a unidirectional
UAS construct inserted upstream of NMMII. elavC155-
Gal4; UASsynaptotagminGFP (elavC155Gal4;UAS-
sytGFP) was obtained from the Bloomington stock cen-
ter (FBst0006923) and UASactinGFP (UAS-actGFP) was
obtained from the Kyoto stock center for FRAP imaging
of vesicle and actin dynamics respectively. A stock of
UAS-actGFP/UAS-actGFP; elav3AGal4/TM3, Sb, Tb was
generated to express actinGFP in the nervous system.
The Gal4 drivers, elav3AGal4 (FBti0072910, Blooming-
ton stock center) and elavC155Gal4 drive expression of
UAS constructs in the nervous system [34]. 24BGal4
(FBti0002090, Bloomington stock center) was used to
drive expression of NMMII alleles in muscle. Flies were
crossed at 25°C and kept at identical growing
conditions.
Immunocytochemistry
Third instar larva were dissected in HL3 buffer with no
Ca2+ added [35], and fixed in 4% paraformaldehyde in
phosphate-buffered saline (PBS). After fixation, the sam-
ples were transferred to 1% BSA diluted in PBT (PBS
plus 0.1% Triton X-100). The following primary antibo-
dies were used: rabbit anti-NMMII (1:1000, Roger Kar-
ess, Centre de National de Récherche Scientifique,
Centre de Génétique Moléculaire), and mouse anti-Dlg
(1:200, Developmental Studies Hybridoma Bank). Anti-
HRP FITC (1:1000, MP Biomedical; Solon, OH) was
used as a neural marker. The secondary antibodies used
were; goat anti-mouse Alexa488 and goat anti-rabbit
Alexa633 (1:1000, Invitrogen). Following antibody label-
ling, the preparations were washed in PBT and mounted
in Vectashield (Vector Laboratories; Burlington, ON).
Images were acquired on a Carl Zeiss LSM510 confocal.
Z-sections were obtained on a F-Fluar 40×/1.3 Oil for
NMMII localization. The pinhole aperture acquired images
of 1 μm thickness and image sections were projected onto
a single plane. 1-3 images were collected per larva.
Western blot
For each treatment, five brains from third instar larvae
were lysed in protein lysis buffer (50 mM Tris-Cl, 1%
NP-40, 150 mM NaCl) with complete protease inhibitor.
Samples were separated on a 10% SDS-polyacrylamide
gel, and transferred to PVDF membrane. NMMII was
detected with rabbit anti-NMMII antibody (1:10000,
Roger Karess, Centre de National de Récherche Scienti-
fique, Centre de Génétique Moléculaire), and a goat
anti-rabbit HRP-coupled secondary (1:1500 BioRad). a-
b-Tubulin was used as a loading control (1:100, Devel-
opmental Studies Hybridoma Bank). Antibodies were
visualized using chemiluminescent detection (ECL Plus,
Amersham). Control and experimental bands were
imaged either simultaneous or individually on the same
blot. Blots were scanned and digitized with a Molecular
Dynamics Phosphoimager. Band intensities were quanti-
fied using ImageJ.
Fluorescence Recovery After Photobleaching
FRAP was conducted on a Carl Zeiss LSM 510 confocal
microscope equipped with an Argon2 laser and a LP505
filter. To immobilize the preparation, wandering third
instar larvae were dissected in HL3 with no Ca2+ added
[35] and glued to slygard-coated slides using Nexabrand
tissue glue (WPI, Sarasota, FL). The glued preparations
were placed under an Achroplan 100×/1.0 W Ph objec-
tive with an 8× digital zoom. FRAP recordings were
made, from segments 3 or 4, of type I boutons at mus-
cle 7/6 for vesicle dynamics. Images were collected at
1.12 μs/pixel with a pinhole of 1 airy unit and a resolu-
tion of 512 × 512. Sixty images were collected over two
minutes with a 1 sec delay between image acquisitions.
To select the area for bleaching, a region of interest
(ROI) 24 × 30 pixels was selected on the digital image.
Four baseline scans were acquired using 5% or 10% of
full laser power. Before the fifth scan, the laser increased
to 97% of maximal and rapidly iterated the ROI 9 times,
after which, returning to 5% or 10% of maximal power
to complete the remaining 56 scans. A maximum of
three type I boutons were recorded per hemi-segment
and a maximum of 6 boutons per larvae. All FRAP
experiments were completed within 2 hours of the larval
dissection.
The acquired image sequences were imported into
ImageJ. Images that drifted were digitally stabilized
before analysis [36]. The time series analyzer plug-in for
ImageJ was used to measure fluorescent intensity. Inten-
sity measurements were taken from the background, the
total fluorescence in the bouton, and the fluorescence in
the bleached area. A double normalization was com-
pleted, as described in [37] using the following equation:
( )( )
( )( )
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Where T = total fluorescence in the bouton, I = fluor-
escence in the bleached fraction and BG = background
fluorescence outside the bouton. This accounts for
photobleaching throughout the FRAP experiment and
for movement of bleached molecules out of the FRAP
ROI.
The recovery curves were fit two a double exponential
curve [38] as follows:
Frap t A e B eK off t K off t( ) ( ) ( )   1 1 2
Where A, B = constants that represent the apparent
bleached fraction, K1, K2 = rates, t = time.
Drug administration
To access vesicle dynamics under myosin inhibition, the
myosin light chain kinase inhibitor, ML-9, was applied
to the preparation before beginning FRAP experiments.
A stock concentration of 50 mM ML-9 in DMSO was
diluted into HL3 [35] with no Ca2+ added, to make
100 μM, 50 μM and 10 μM ML-9 solutions. The pre-
parations were incubated in the dark with ML-9 for 30
minutes prior to FRAP.
Statistical analysis
All statistical analyses were performed in GraphPad
Prism 4.0. For non-linear regression, FRAP was double
normalized [37] and compiled for curve fitting [38]. In
all cases, the double exponential curve outlined in
McNally (2008) [38] was accepted over the single expo-
nential curve. Error is represented as the 95% confi-
dence interval for the curve. Rates are expressed as
inverse seconds. In double exponential curves, the initial
phase has been indicated here with A and K1 and the
second phase of the curve have been indicated by B and
K2. For analysis of variance, one-way ANOVA was com-
pleted. P < 0.05 was accepted as statistically significant.
Additional file 1: Movie 1. FRAP of synaptic vesicles labelled with
synaptotagmin-GFP. Time-lapse video recorded over two minutes and
compressed into 9 seconds.
Additional file 2: Movie 2. FRAP of labelled synaptic vesicles whose
mobility has been inhibited with application of 100 μM ML-9. Time-lapse
video recorded over two minutes and compressed into 9 seconds.
Additional file 3: Movie 3. FRAP of labelled synaptic vesicles showing
that mobility is reduced with RNAi knockdown of NMMII. Time-lapse
video recorded over two minutes and compressed into 9 seconds.
Additional file 4: Movie 4. FRAP of labelled synaptic vesicles whose
mobility is enhanced with a moderate reduction of NMMII. Time-lapse
video recorded over two minutes and compressed into 9 seconds.
Additional file 5: Movie 5. FRAP of synaptotagmin-GFP labelled vesicles
showing reduced vesicle mobility with overexpression of NMMII. Time-
lapse video recorded over two minutes and compressed into 9 seconds.
Additional file 6: Figure S1. Graphs indicating the average bleach
depth and the recovery index for the NMMII FRAP experiments.
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